Loading
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Latest quote
$12.39
−$0.37 · -2.90%
After-hours
$12.39
$0.00 · 0.00%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Day range
Current $12.39
52-week range
Current $12.39
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
75
Undervalued
Sentiment
59
Mixed
Risk
51
Elevated Risk
Momentum
50
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Day range
Current $12.39
52-week range
Current $12.39
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 99.99M USD | 79.91M USD | 65.42M USD | 45.52M USD | 45.18M USD |
| Cost of goods sold | 22.77M USD | 20.82M USD | 17.3M USD | 13.03M USD | 11.75M USD |
| Gross profit | 77.22M USD | 59.09M USD | 48.12M USD | 32.49M USD | 33.44M USD |
| Research and development | 27.89M USD | 23.65M USD | 20.78M USD | 21.95M USD | 18.21M USD |
| Selling, general, and administrative | 65.67M USD | 57.1M USD | 54.52M USD | 51.34M USD | 38.96M USD |
| Operating expenses | 93.56M USD | 80.76M USD | 75.3M USD | 73.29M USD | 57.17M USD |
| Interest income | 2.82M USD | 3.02M USD | 3.05M USD | 1.58M USD | 448K USD |
| Interest expense | 7.46M USD | 8.8M USD | 8.52M USD | 7.53M USD | 7.41M USD |
| Depreciation and amortization | 1.95M USD | 1.77M USD | 1.61M USD | 2.99M USD | 296K USD |
| Operating income | −16.34M USD | −21.67M USD | −27.17M USD | −40.79M USD | −23.74M USD |
| Net income | −21.47M USD | −27.14M USD | −32.96M USD | −47.08M USD | −36.08M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.25
63.44% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI13.31M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM8.96M0.01%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF4.32M0.00%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO3.08M0.02%14.04B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO2.23M0.01%18B USD0.06%$112.1-0.10%
iShares Micro-Cap ETFIWC1.06M0.08%1.33B USD0.60%$182.79-0.31%
State Street SPDR S&P Health Care Equipment ETFXHE619.17K0.35%178.43M USD0.35%$88.14-0.18%
Vanguard Russell 2000 Growth ETFVTWG420K0.02%1.7B USD0.06%$258.14-0.44%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCState Street SPDR S&P Health Care Equipment ETFXHEVanguard Russell 2000 Growth ETFVTWGAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
